Skip to content

US · ENTA · BIOTECHNOLOGY

Enanta Pharmaceuticals, Inc. (ENTA) intrinsic value and stock valuation

$7.62as of 2026-11-21 · Mkt cap 400.41M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Enanta Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ENTA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ENTA’s statements →

Enanta Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02472 enanta.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$65.3M-11.8% 5y CAGRd
20112025
Net income
-$-81.89M
20112025
Free cash flow
-$-32.17M
20112025
Total equity
$64.7M-32.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$65.3M$67.6M$79.2M$86.2M$97.1M
Operating income-$-85.35M-$-121.69M-$-137.21M-$-123.84M-$-109.57M
Net income-$-81.89M-$-116.05M-$-133.82M-$-121.75M-$-79M
EPSd-$-3.84M-$-5.48M-$-6.38M-$-5.91M-$-3.92M
Operating cash flow-$-19.27M-$-78.76M-$-103.15M-$-84.78M-$-70M
Capital expenditure-$-12.9M-$-17.95M-$-9.06M-$-2.12M-$-750K
Free cash flow-$-32.17M-$-96.71M-$-112.21M-$-86.91M-$-70.75M
Total assets$280.7M$376.7M$462.3M$380.6M$440.9M
Total debt$201.1M$226.1M$26.5M$26.7M$6.83M
Net debt$168.8M$188.8M-$-58.88M-$-17.31M-$-50.37M
Total equity$64.7M$128.8M$216.7M$321.3M$399.4M
Cash and short-term investments$188.9M$248.2M$369.9M$249.2M$244M
Income statement
20252024202320222021
Revenue$65.3M$67.6M$79.2M$86.2M$97.1M
Cost of revenue$4.59M$0.00$0.00$0.00$0.00
Gross profit$60.7M$67.6M$79.2M$86.2M$97.1M
Research and development expenses$106.7M$131.5M$163.5M$164.5M$174.1M
Selling, general and administrative expenses$43.9M$57.9M$52.9M$45.5M$32.5M
Other expenses-$-4.59M$0.00$0.00$0.00$0.00
Operating expenses$146.1M$189.3M$216.4M$210M$206.7M
Cost and expenses$150.7M$189.3M$216.4M$210M$206.7M
Interest income$9.48M$14.8M$11.4M$1.57M$2.02M
Interest expense$7.68M$10.9M$5.15M$0.00$0.00
Depreciation and amortization$5.09M$2.34M$2.37M$2.97M$3.33M
Ebitda-$-70.78M-$-104.51M-$-123.48M-$-119.22M-$-104.25M
Operating income-$-85.35M-$-121.69M-$-137.21M-$-123.84M-$-109.57M
Total other income/expenses, net$1.8M$3.9M$6.21M$1.66M$1.99M
Income before tax-$-83.55M-$-117.79M-$-131M-$-122.19M-$-107.58M
Income tax expense-$-1.66M-$-1.74M$2.82M-$-430K-$-28.58M
Net income-$-81.89M-$-116.05M-$-133.82M-$-121.75M-$-79M
Weighted average shares outstanding$21.3M$21.2M$21M$20.6M$20.2M
Weighted average diluted shares outstanding$21.3M$21.2M$21M$20.6M$20.2M
Balance sheet
20252024202320222021
Cash and short-term investments$188.9M$248.2M$369.9M$249.2M$244M
Net receivables$6.88M$38.7M$39.6M$49M$60.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$204.3M$299.9M$422.8M$311.7M$319M
Property, plant and equipment, net$72.9M$73.4M$34.7M$29.8M$10.7M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$3.36M$3.36M$3.97M$33.3M$109M
Total non-current assets$76.4M$76.8M$39.5M$68.9M$121.8M
Total assets$280.7M$376.7M$462.3M$380.6M$440.9M
Accounts payable$1.95M$8M$4.1M$6M$9.54M
Short-term debt$33.9M$36M$5.28M$2.89M$4.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$48.6M$57.5M$62.8M$29.8M$36.2M
Long-term debt$167.2M$190.1M$21.2M$23.8M$2.63M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$167.5M$190.3M$182.8M$29.4M$5.26M
Capital lease obligations$57.9M$55.5M$26.5M$25.3M$5.33M
Total liabilities$216M$247.8M$245.5M$59.3M$41.4M
Common stock$210K$210K$210K$210K$200K
Retained earnings-$-404.93M-$-323.04M-$-207M-$-73.18M$48.6M
Accumulated other comprehensive income (loss)-$-340K$300K-$-1.17M-$-3.72M-$-380K
Total equity$64.7M$128.8M$216.7M$321.3M$399.4M
Total investments$159.9M$214.3M$288.5M$238.5M$295.8M
Total debt$201.1M$226.1M$26.5M$26.7M$6.83M
Net debt$168.8M$188.8M-$-58.88M-$-17.31M-$-50.37M
Cash flow statement
20252024202320222021
Net income-$-81.89M-$-116.05M-$-133.82M-$-121.75M-$-79M
Depreciation and amortization$5.09M$2.34M$2.37M$2.97M$3.33M
Stock-based compensation$18.6M$26.8M$28.2M$27M$21M
Change in working capital$39.9M$7.13M$8.02M$6.79M-$-13.69M
Accounts receivable$31.8M$970K$9.42M$11.8M-$-24.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.31M-$-410K-$-1.15M-$-4.63M$3.77M
Net cash provided by operating activities-$-19.27M-$-78.76M-$-103.15M-$-84.78M-$-70M
Investments in property, plant and equipment-$-12.9M-$-17.95M-$-9.06M-$-2.12M-$-750K
Acquisitions, net$0.00$0.00$44.5M-$-54.9M-$-37.74M
Net cash used for investing activities$40.4M$58.2M-$-53.58M$54.9M$37M
Common stock issued$140K$150K$2.21M$21.3M$3.61M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-26.62M-$-27.63M$198.1M$20M$3.08M
Net change in cash-$-5.54M-$-48.16M$41.4M-$-9.85M-$-29.93M
Cash at end of period$35.7M$41.2M$89.4M$48M$57.8M
Operating cash flow-$-19.27M-$-78.76M-$-103.15M-$-84.78M-$-70M
Capital expenditure-$-12.9M-$-17.95M-$-9.06M-$-2.12M-$-750K
Free cash flow-$-32.17M-$-96.71M-$-112.21M-$-86.91M-$-70.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Enanta Pharmaceuticals, Inc.

        Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

        CEO
        Jay R. Luly
        Employees
        120
        Beta
        0.97

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Enanta Pharmaceuticals, Inc. (ENTA)?

        Enanta Pharmaceuticals, Inc. (ENTA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ENTA undervalued?

        ENTA trades at a price of $7.62 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.